ACADIA PHARMACEUTICALS INC. Increase (Decrease) in Accrued Liabilities
ACADIA PHARMACEUTICALS INC. (ACAD) reported Increase (Decrease) in Accrued Liabilities of $46.09 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilities · last filed 2026-08-05
- ACADIA PHARMACEUTICALS INC. increase (decrease) in accrued liabilities for the quarter ending 2026-06-30 was $22.53M, a 4.96% increase year-over-year.
- ACADIA PHARMACEUTICALS INC. increase (decrease) in accrued liabilities for the quarter ending 2026-03-31 was $23.56M.
- ACADIA PHARMACEUTICALS INC. increase (decrease) in accrued liabilities for the quarter ending 2025-12-31 was -$68.39M, a 322.22% decline year-over-year.
- ACADIA PHARMACEUTICALS INC. increase (decrease) in accrued liabilities for the quarter ending 2025-09-30 was $27.78M, a 109.76% increase year-over-year.
- ACADIA PHARMACEUTICALS INC. increase (decrease) in accrued liabilities for fiscal 2025 was -$19.27M, a 127.11% decline from fiscal 2024.
- ACADIA PHARMACEUTICALS INC. increase (decrease) in accrued liabilities for fiscal 2024 was $71.06M, a 23.73% decline from fiscal 2023.
- ACADIA PHARMACEUTICALS INC. increase (decrease) in accrued liabilities for fiscal 2023 was $93.17M, a 283.32% increase from fiscal 2022.
- ACADIA PHARMACEUTICALS INC. increase (decrease) in accrued liabilities for fiscal 2022 was $24.31M.
| Period end | Increase (Decrease) in Accrued Liabilities 3 month | Increase (Decrease) in Accrued Liabilities 6 month | Increase (Decrease) in Accrued Liabilities 9 month | Increase (Decrease) in Accrued Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $22.53M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $46.09M 10-Q · filed 2026-08-05 | -$22.30M derived: sum of 3 quarters · filed 2026-08-05 | $5.47M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $23.56M 10-Q · filed 2026-05-07 | -$44.83M derived: sum of 2 quarters · filed 2026-05-07 | -$17.06M derived: sum of 3 quarters · filed 2026-05-07 | $4.41M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | -$68.39M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$40.62M derived: sum of 2 quarters · filed 2026-02-26 | -$19.15M derived: sum of 3 quarters · filed 2026-08-05 | -$19.27M 10-K · filed 2026-02-26 |
| 2025-09-30 | $27.78M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $49.24M derived: sum of 2 quarters · filed 2026-08-05 | $49.13M 10-Q · filed 2025-11-06 | $79.90M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $21.47M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $21.35M 10-Q · filed 2026-08-05 | $52.13M derived: sum of 3 quarters · filed 2026-08-05 | $65.37M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | -$116.00K 10-Q · filed 2026-05-07 | $30.66M derived: sum of 2 quarters · filed 2026-05-07 | $43.90M derived: sum of 3 quarters · filed 2026-05-07 | $58.75M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $30.78M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $44.02M derived: sum of 2 quarters · filed 2026-02-26 | $58.87M derived: sum of 3 quarters · filed 2026-02-26 | $71.06M 10-K · filed 2026-02-26 |
| 2024-09-30 | $13.24M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $28.09M derived: sum of 2 quarters · filed 2025-11-06 | $40.28M 10-Q · filed 2025-11-06 | $78.42M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $14.85M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $27.04M 10-Q · filed 2025-08-07 | $65.18M derived: sum of 3 quarters · filed 2026-02-26 | $93.34M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $12.19M 10-Q · filed 2025-05-08 | $50.33M derived: sum of 2 quarters · filed 2026-02-26 | $78.49M derived: sum of 3 quarters · filed 2026-02-26 | $80.85M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $38.13M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $66.30M derived: sum of 2 quarters · filed 2026-02-26 | $68.66M derived: sum of 3 quarters · filed 2026-02-26 | $93.17M 10-K · filed 2026-02-26 |
| 2023-09-30 | $28.16M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $30.53M derived: sum of 2 quarters · filed 2024-11-07 | $55.04M 10-Q · filed 2024-11-07 | $61.57M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $2.37M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $26.88M 10-Q · filed 2024-08-07 | $33.41M derived: sum of 3 quarters · filed 2025-02-27 | $34.33M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $24.51M 10-Q · filed 2024-05-09 | $31.05M derived: sum of 2 quarters · filed 2025-02-27 | $31.96M derived: sum of 3 quarters · filed 2025-02-27 | $29.14M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $6.54M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $7.45M derived: sum of 2 quarters · filed 2025-02-27 | $4.63M derived: sum of 3 quarters · filed 2025-02-27 | $24.31M 10-K · filed 2025-02-27 |
| 2022-09-30 | $917.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | -$1.90M derived: sum of 2 quarters · filed 2023-11-03 | $17.77M 10-Q · filed 2023-11-03 | $26.58M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | -$2.82M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $16.85M 10-Q · filed 2023-08-03 | $25.66M derived: sum of 3 quarters · filed 2024-02-28 | $19.73M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | $19.67M 10-Q · filed 2023-05-08 | $28.48M derived: sum of 2 quarters · filed 2024-02-28 | $22.55M derived: sum of 3 quarters · filed 2024-02-28 | $8.46M derived: sum of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | $8.80M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $2.88M derived: sum of 2 quarters · filed 2024-02-28 | -$11.22M derived: sum of 3 quarters · filed 2024-02-28 | -$8.46M 10-K · filed 2024-02-28 |
| 2021-09-30 | -$5.93M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | -$20.02M derived: sum of 2 quarters · filed 2022-11-03 | -$17.26M 10-Q · filed 2022-11-03 | -$7.54M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | -$14.09M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | -$11.33M 10-Q · filed 2022-08-09 | -$1.61M derived: sum of 3 quarters · filed 2023-02-28 | $4.38M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | $2.76M 10-Q · filed 2022-05-05 | $12.48M derived: sum of 2 quarters · filed 2023-02-28 | $18.48M derived: sum of 3 quarters · filed 2023-02-28 | $6.27M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | $9.72M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $15.72M derived: sum of 2 quarters · filed 2023-02-28 | $3.51M derived: sum of 3 quarters · filed 2023-02-28 | $27.57M 10-K · filed 2023-02-28 |
| 2020-09-30 | $6.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | -$6.20M derived: sum of 2 quarters · filed 2021-11-09 | $17.85M 10-Q · filed 2021-11-09 | $21.01M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | -$12.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $11.85M 10-Q · filed 2021-08-05 | $15.01M derived: sum of 3 quarters · filed 2022-03-01 | $19.89M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | $24.06M 10-Q · filed 2021-05-06 | $27.21M derived: sum of 2 quarters · filed 2022-03-01 | $32.09M derived: sum of 3 quarters · filed 2022-03-01 | $19.48M derived: sum of 4 quarters · filed 2022-03-01 |
| 2019-12-31 | $3.16M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $8.03M derived: sum of 2 quarters · filed 2022-03-01 | -$4.58M derived: sum of 3 quarters · filed 2022-03-01 | $6.46M 10-K · filed 2022-03-01 |
| 2019-09-30 | $4.88M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-04 | -$7.73M derived: sum of 2 quarters · filed 2020-11-04 | $3.30M 10-Q · filed 2020-11-04 | $20.94M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-06-30 | -$12.61M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | -$1.58M 10-Q · filed 2020-08-06 | $16.07M derived: sum of 3 quarters · filed 2021-02-25 | $9.01M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-03-31 | $11.04M 10-Q · filed 2020-05-08 | $28.68M derived: sum of 2 quarters · filed 2021-02-25 | $21.62M derived: sum of 3 quarters · filed 2021-02-25 | $24.18M derived: sum of 4 quarters · filed 2021-02-25 |
| 2018-12-31 | $17.64M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $10.59M derived: sum of 2 quarters · filed 2021-02-25 | $13.14M derived: sum of 3 quarters · filed 2021-02-25 | $15.99M 10-K · filed 2021-02-25 |
| 2018-09-30 | -$7.05M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-31 | -$4.50M derived: sum of 2 quarters · filed 2019-10-31 | -$1.65M 10-Q · filed 2019-10-31 | $5.42M derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-06-30 | $2.56M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-01 | $5.41M 10-Q · filed 2019-08-01 | $12.47M derived: sum of 3 quarters · filed 2020-02-27 | $8.36M derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-03-31 | $2.85M 10-Q · filed 2019-05-02 | $9.91M derived: sum of 2 quarters · filed 2020-02-27 | $5.80M derived: sum of 3 quarters · filed 2020-02-27 | $4.14M derived: sum of 4 quarters · filed 2020-02-27 |
| 2017-12-31 | $7.06M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | $2.95M derived: sum of 2 quarters · filed 2020-02-27 | $1.29M derived: sum of 3 quarters · filed 2020-02-27 | $4.21M 10-K · filed 2020-02-27 |
| 2017-09-30 | -$4.11M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | -$5.77M derived: sum of 2 quarters · filed 2018-11-06 | -$2.86M 10-Q · filed 2018-11-06 | -$1.37M derived: sum of 4 quarters · filed 2019-02-27 |
| 2017-06-30 | -$1.66M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-08 | $1.25M 10-Q · filed 2018-08-08 | $2.74M derived: sum of 3 quarters · filed 2019-02-27 | $9.83M derived: sum of 4 quarters · filed 2019-02-27 |
| 2017-03-31 | $2.92M 10-Q · filed 2018-05-04 | $4.41M derived: sum of 2 quarters · filed 2019-02-27 | $11.49M derived: sum of 3 quarters · filed 2019-02-27 | $19.27M derived: sum of 4 quarters · filed 2019-02-27 |
| 2016-12-31 | $1.49M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-27 | $8.58M derived: sum of 2 quarters · filed 2019-02-27 | $16.35M derived: sum of 3 quarters · filed 2019-02-27 | $15.58M 10-K · filed 2019-02-27 |
| 2016-09-30 | $7.09M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | $14.86M derived: sum of 2 quarters · filed 2017-11-07 | $14.09M 10-Q · filed 2017-11-07 | $18.77M derived: sum of 4 quarters · filed 2018-02-27 |
| 2016-06-30 | $7.77M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-08 | $7.00M 10-Q · filed 2017-08-08 | $11.69M derived: sum of 3 quarters · filed 2018-02-27 | $10.61M derived: sum of 4 quarters · filed 2018-02-27 |
| 2016-03-31 | -$771.00K 10-Q · filed 2017-05-09 | $3.91M derived: sum of 2 quarters · filed 2018-02-27 | $2.84M derived: sum of 3 quarters · filed 2018-02-27 | $5.44M derived: sum of 4 quarters · filed 2018-02-27 |
| 2015-12-31 | $4.68M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27 | $3.61M derived: sum of 2 quarters · filed 2018-02-27 | $6.21M derived: sum of 3 quarters · filed 2018-02-27 | $6.26M 10-K · filed 2018-02-27 |
| 2015-09-30 | -$1.07M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-07 | $1.53M derived: sum of 2 quarters · filed 2016-11-07 | $1.57M 10-Q · filed 2016-11-07 | $5.26M derived: sum of 4 quarters · filed 2017-02-28 |
| 2015-06-30 | $2.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04 | $2.64M 10-Q · filed 2016-08-04 | $6.33M derived: sum of 3 quarters · filed 2017-02-28 | $8.26M derived: sum of 4 quarters · filed 2017-02-28 |
| 2015-03-31 | $42.00K 10-Q · filed 2016-05-05 | $3.73M derived: sum of 2 quarters · filed 2017-02-28 | $5.65M derived: sum of 3 quarters · filed 2017-02-28 | $7.43M derived: sum of 4 quarters · filed 2017-02-28 |
| 2014-12-31 | $3.69M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-28 | $5.61M derived: sum of 2 quarters · filed 2017-02-28 | $7.39M derived: sum of 3 quarters · filed 2017-02-28 | $7.27M 10-K · filed 2017-02-28 |
| 2014-09-30 | $1.92M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-05 | $3.70M derived: sum of 2 quarters · filed 2015-11-05 | $3.58M 10-Q · filed 2015-11-05 | $3.46M derived: sum of 4 quarters · filed 2016-02-29 |
| 2014-06-30 | $1.78M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-06 | $1.65M 10-Q · filed 2015-08-06 | $1.54M derived: sum of 3 quarters · filed 2016-02-29 | $1.72M derived: sum of 4 quarters · filed 2016-02-29 |
| 2014-03-31 | -$123.00K 10-Q · filed 2015-05-07 | -$241.00K derived: sum of 2 quarters · filed 2016-02-29 | -$59.00K derived: sum of 3 quarters · filed 2016-02-29 | $2.27M derived: sum of 4 quarters · filed 2016-02-29 |
| 2013-12-31 | -$118.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | $64.00K derived: sum of 2 quarters · filed 2016-02-29 | $2.39M derived: sum of 3 quarters · filed 2016-02-29 | $2.41M 10-K · filed 2016-02-29 |
| 2013-09-30 | $182.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-10 | $2.51M derived: sum of 2 quarters · filed 2014-11-10 | $2.53M 10-Q · filed 2014-11-10 | $1.98M derived: sum of 4 quarters · filed 2015-02-26 |
| 2013-06-30 | $2.33M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-05 | $2.35M 10-Q · filed 2014-08-05 | $1.80M derived: sum of 3 quarters · filed 2015-02-26 | $1.26M derived: sum of 4 quarters · filed 2015-02-26 |
| 2013-03-31 | $20.00K 10-Q · filed 2014-05-06 | -$527.00K derived: sum of 2 quarters · filed 2015-02-26 | -$1.07M derived: sum of 3 quarters · filed 2015-02-26 | -$534.00K derived: sum of 4 quarters · filed 2015-02-26 |
| 2012-12-31 | -$547.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-26 | -$1.09M derived: sum of 2 quarters · filed 2015-02-26 | -$554.00K derived: sum of 3 quarters · filed 2015-02-26 | $635.00K 10-K · filed 2015-02-26 |
| 2012-09-30 | -$539.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-06 | -$7.00K derived: sum of 2 quarters · filed 2013-11-06 | $1.18M 10-Q · filed 2013-11-06 | $284.00K derived: sum of 4 quarters · filed 2014-02-27 |
| 2012-06-30 | $532.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-06 | $1.72M 10-Q · filed 2013-08-06 | $823.00K derived: sum of 3 quarters · filed 2014-02-27 | $1.21M derived: sum of 4 quarters · filed 2014-02-27 |
| 2012-03-31 | $1.19M 10-Q · filed 2013-05-07 | $291.00K derived: sum of 2 quarters · filed 2014-02-27 | $680.00K derived: sum of 3 quarters · filed 2014-02-27 | $440.00K derived: sum of 4 quarters · filed 2014-02-27 |
| 2011-12-31 | -$898.00K derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-27 | -$509.00K derived: sum of 2 quarters · filed 2014-02-27 | -$749.00K derived: sum of 3 quarters · filed 2014-02-27 | $277.00K 10-K · filed 2014-02-27 |
| 2011-09-30 | $389.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-05 | $149.00K derived: sum of 2 quarters · filed 2012-11-05 | $1.18M 10-Q · filed 2012-11-05 | $633.00K derived: sum of 4 quarters · filed 2013-03-12 |
| 2011-06-30 | -$240.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-08 | $786.00K 10-Q · filed 2012-08-08 | $244.00K derived: sum of 3 quarters · filed 2013-03-12 | -$141.00K derived: sum of 4 quarters · filed 2013-03-12 |
| 2011-03-31 | $1.03M 10-Q · filed 2012-05-08 | $484.00K derived: sum of 2 quarters · filed 2013-03-12 | $99.00K derived: sum of 3 quarters · filed 2013-03-12 | |
| 2010-12-31 | -$542.00K derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-12 | -$927.00K derived: sum of 2 quarters · filed 2013-03-12 | -$2.13M 10-K · filed 2013-03-12 | |
| 2010-09-30 | -$385.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-09 | -$1.59M 10-Q · filed 2011-11-09 | ||
| 2010-06-30 | -$1.21M 10-Q · filed 2011-08-10 | |||
| 2009-12-31 | -$2.28M 10-K · filed 2012-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |